You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
A pair of studies published this week present an analysis of a real, large-scale testing pooling effort as well as analyses of how to further improve such strategies.
The partners will research the ability of Biocept's Target Selector molecular assay to determine EGFR status in non-small cell lung cancer patients.
The Spanish firm also expects to release clinical data on its early-stage, next-generation sequencing-based colorectal cancer test in the first half of 2021.
The organization intends to deploy a prototype of the platform in Brussels Airport next summer.
The assay underwent clinical validation at three centers in Singapore and 5,248 patients were ultimately screened using the test.
The firm reported $2 billion in third-quarter revenues related to the COVID-19 response, accounting for 23 percent of its overall revenues.
The company reported net income of $1.93 billion, or $4.84 per share, compared to $760 million, or $1.89 per share, for the year-ago quarter.
The effort, called INNO4COV-19, was awarded €6.1 million last month to support the commercialization of new diagnostics.
The firm said its coronavirus assay targets the nucleocapsid and envelope virus genes and is compatible with most RNA extraction methods and qPCR instruments.
Of the 28 companies in the index, 18 firms saw their stock prices increase, while 10 firms' share prices decreased.